EGF receptor family: Twisting targets for improved cancer therapies

Growth Factors

Volumn 32, Issue 2, 2014, Pages 74-81

  Burgess, Antony W ^a   Henis, Yoav I ^b   Hynes, Nancy E ^c   Jovin, Thomas ^d   Levitzki, Alexander ^e   Pinkas Kramarski, Ronit ^b   Yarden, Yosef ^f  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b TEL AVIV UNIVERSITY   (Israel)

^c FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^d MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^e HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^f WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Cell surface; ErbB2; ErbB3; FLIM; FRET; Receptor dynamics; Therapeutic antibodies

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; LIGAND; NANOBODY; PERTUZUMAB; PROTEIN P53; QUANTUM DOT; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ARTICLE; CANCER THERAPY; CELL MIGRATION; CELL SURFACE; DRUG TARGETING; HUMAN; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; HUMANS; MEMBRANE PROTEINS; MICE; NEOPLASMS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84896904110     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2014.896355     Document Type: Article

References (60)

1. Alvarado D, Klein DE, Lemmon MA. 2010. Structural basis for negative cooperativity in growth factor binding to an EGF receptor. Cell 142: 568-579.
2. Arkhipov A, Shan Y, Das R, Endres NF, Eastwood MP, Wemmer DE, Kuriyan J, et al. 2013. Architecture and membrane interactions of the EGF receptor. Cell 152:557-569.
3. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. 2012. Treatment of HER2-positive breast cancer: Current status and future perspectives. Nature Rev Clin Oncol 9:16-32.
4. Bagchi A, Bessman NJ, Wu NZ, Raines L, Kan Z, Hu W, Englander W, et al. 2014. Allosteric regulation of the epidermal growth factor receptor. Biophys J 106:105a.
5. Ben-Chetrit N, Tarcic G, Yarden Y. 2013. ERK-ERF-EGR1, a novel switch underlying acquisition of a motile phenotype. Cell Adh Migr 7: 33-37.
6. Blair BG, Bardelli A, Park BH. 2014. Somatic alterations as the basis for resistance to targeted therapies. J Pathol 232:244-254.
7. Blümer J, Rey J, Dehmelt L, Mazel T, Wu YW, Bastiaens P, Goody RS, et al. 2013. RabGEFs are a major determinant for specific Rab membrane targeting. J Cell Biol 200:287-300.
8. Chung I, Reichelt M, Dowbenko D, Mellman I, Sliwkowski M. 2014. HER2 overexpression induces membrane deformation that increases cell motility. Biophys J 106:523a.
9. Coskun Ü, Grzybek M, Drechsel D, Simons K. 2011. Regulation of human EGF receptor by lipids. Proc Natl Acad Sci 108:9044-9048.
10. Cutler PJ, Malik MD, Liu S, Byars JM, Lidke DS, Lidke KA. 2013. Multi-color quantum dot tracking using a high-speed hyperspectral line-scanning microscope. PLoS One 8:e64320.
11. DiGiulio S. 2013. FDA approves Kadcyla (T-DM1) for late-stage breast cancer. Oncology Times 35:21.
12. Ehrlich M, Horbelt D, Marom B, Knauz P, Henis YI. 2011. Homomeric and heteromeric complexes among TGF-β and BMP receptors and their roles in signaling. Cell Signal 23:1424-1432.
13. Endres NF, Das R, Smith AW, Arkhipov A, Kovacs E, Huang Y, Pelton JG, et al. 2013. Conformational coupling across the plasma membrane in activation of the EGF receptor. Cell 152:543-556.
14. Faigenbaum R, Haklai R, Ben-Baruch G, Kloog Y. 2013. Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib. Oncotarget 4:316-328.
15. Fortian A, Sorkin A. 2014. Live-cell fluorescence imaging reveals high stoichiometry of Grb2 binding to the EGF receptor sustained during endocytosis. J Cell Sci 127:432-444.
16. Gan HK, Burgess AW, Clayton AH, Scott AM. 2012. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res 72:2924-2930.
17. Haenzi B, Bonny O, Masson R, Lienhard S, Dey JH, Kuro-o M, Hynes NE. 2014. Loss of Memo, a novel FGFR regulator, results in reduced lifespan. FASEB J 28:327-336.
18. Hirokawa Y, Yip K, Tan CW, Burgess AW. 2014. Colonic myofibroblast cell line stimulates colonoid formation. Am J Physiol Gastrointestinal Liver Physiol. [Epub ahead of print]. doi: 10.1152/ajpgi.00267.2013.
19. Hu H, Goltsov A, Bown JL, Sims AH, Langdon SP, Harrison DJ, Faratian D. 2013. Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer. Cellular Signal 25: 26-32.
20. Huang F, Zeng X, Kim W, Balasubramani M, Fortian A, Gygi SP, Yates NA, et al. 2013. Lysine 63-linked polyubiquitination is required for EGF receptor degradation. Proc Natl Acad Sci U S A 110: 15722-15727.
21. Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, Chaudhuri S, et al. 2013. Oncogenic ERBB3 mutations in human cancers. Cancer Cell 23:603-617.
22. Jiang K, Yang Z, Cheng L, Wang S, Ning K, Zhou L, Lin J, et al. 2013. Mediator of ERBB2-driven cell motility (MEMO) promotes extranuclear estrogen receptor signaling involving the growth factor receptors IGF1R and ERBB2. J Biolog Chem 288:24590-24599.
23. Johns TG, McKay MJ, Cvrljevic AN, Gan HK, Taylor C, Xu H, Smyth FE, et al. 2010. MAb 806 enhances the efficacy of ionizing radiation in glioma xenografts expressing the de2-7 epidermal growth factor receptor. Int J Radiation Oncol Biol Phys 78:572-578.
24. Jost C, Schilling J, Tamaskovic R, Schwill M, Honegger A, Plückthun A. 2013. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2. Structure 21:1979-1991.
25. Kamath AV, Lu D, Gupta P, Jin D, Xiang H, Wong A, Leddy C, et al. 2012. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. Cancer Chemother Pharmacol 69:1063-1069.
26. Klinger B, Sieber A, Fritsche-Guenther R, Witzel F, Berry L, Schumacher D, Yan Y, et al. 2013. Network quantification of EGFR signaling unveils potential for targeted combination therapy. Molec Syst Biol 9:673.
27. Kozer N, Barua D, Orchard S, Nice EC, Burgess AW, Hlavacek WS, Clayton AH. 2013. Exploring higher-order EGFR oligomerisation and phosphorylation-A combined experimental and theoretical approach. Molec BioSystems 9:1849-1863.
28. Leahy DJ. 2013. Piecing together the extracellular puzzle. Cell 154: 23-25.
29. Lee FT, O'Keefe GJ, Gan HK, Mountain AJ, Jones GR, Saunder TH, Sagona J, et al. 2010. Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806. J Nucl Med 51:967-972.
30. Liu P, Cleveland TE, Bouyain S, Byrne PO, Longo PA, Leahy DJ. 2012. A single ligand is sufficient to activate EGFR dimers. Proc Natl Acad Sci 109:10861-10866.
31. Lorenz S, Cantor AJ, Rape M, Kuriyan J. 2013. Macromolecular juggling by ubiquitylation enzymes. BMC Biol 11:65.
32. Makki N, Thiel KW, Miller FJ. 2013. The epidermal growth factor receptor and its ligands in cardiovascular disease. Intl J Molec Sci 14: 20597-20613.
33. Marone R, Hess D, Dankort D, Muller WJ, Hynes NE, Badache A. 2004. Memo mediates ErbB2-driven cell motility. Nature Cell Biol 6: 515-522. (Pubitemid 38786594)
34. Mellman I, Yarden Y. 2013. Endocytosis and cancer. Cold Spring Harb Perspect Biol 5:a016949.
35. Mendelsohn J. 2013. Personalizing oncology: Perspectives and prospects. J Clin Oncol 31:1904-1911.
36. Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, et al. 2013. Abstract C94: Heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer are sensitive to concomitant inhibition of EGFR and MEK. Molec Cancer Ther 12: C94-C94.
37. Needham SR, Hirsch M, Rolfe DJ, Clarke DT, Zanetti-Domingues LC, Wareham R, Martin-Fernandez ML. 2013. Measuring EGFR separations on cells with ~10 nm resolution via fluorophore localization imaging with photobleaching. PLoS One 8:e62331.
38. Nguyen LK, Kolch W, Kholodenko BN. 2013. When ubiquitination meets phosphorylation: A systems biology perspective of EGFR/MAPK signalling. Cell Commun Signal 11:52.
39. Phillips GDL, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, Andre F, et al. 2014. Dual Targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: Critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res 20:456-468.
40. Powell AE, Wang Y, Li Y, Poulin EJ, Means AL, Washington MK, Higginbotham JN, et al. 2012. The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell 149:146-158.
41. Rolfe DJ, McLachlan CI, Hirsch M, Needham SR, Tynan CJ, Webb SE, Martin-Fernandez ML, et al. 2011. Automated multidimensional single molecule fluorescence microscopy feature detection and tracking. Eur Biophys J 40:1167-1186.
42. Schlatter ID, Meira M, Ueberschlag V, Hoepfner D, Movva R, Hynes NE. 2012. MHO1, an evolutionarily conserved gene, is synthetic lethal with PLC1; Mho1p has a role in invasive growth. PLoS One 7: e32501.
43. Schmitz KR, Bagchi A, Roovers RC, van Bergen en Henegouwen PM, Ferguson KM. 2013. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains. Structure 21:1214-1224.
44. Schokoroy S, Juster D, Kloog Y, Pinkas-Kramarski R. 2013. Disrupting the oncogenic synergism between nucleolin and Ras results in cell growth inhibition and cell death. PLoS One 8:e75269.
45. Schreier B, Rabe S, Schneider B, Bretschneider M, Rupp S, Ruhs S, Neumann J, et al. 2013. Loss of epidermal growth factor receptor in vascular smooth muscle cells and cardiomyocytes causes arterial hypotension and cardiac hypertrophy. Hypertension 61:333-340.
46. Sezgin E, Levental I, Grzybek M, Schwarzmann G, Mueller V, Honigmann A, Belov VN, et al. 2012. Partitioning, diffusion, and ligand binding of raft lipid analogs in model and cellular plasma membranes. Biochim Biophys Acta 1818: 1777-1784.
47. Shen J, Xia W, Khotskaya YB, Huo L, Nakanishi K, Lim SO, Du Y, et al. 2013. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 497:383-387.
48. Sliwkowski MX. 2012. Pari passu dimers of dimers. Proc Natl Acad Sci USA 109:13140-13141.
49. Sorkin A, Puthenveedu MA. 2013. Clathrin-mediated endocytosis. In: Yarden Y, Tarcic G, Editors. Vesicle Trafficking in Cancer. New York: Springer.
50. Tan CW, Hirokawa Y, Gardiner BS, Smith DW, Burgess AW. 2013. Colon cryptogenesis: Asymmetric budding. PLoS One 8:e78519.
51. Valley CC, Lidke KA, Lidke DS. 2013. The spatiotemporal organization of ErbB receptors: Insights from microscopy. Cold Spring Harbor Perspect Biol 6:a020735.
52. Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, Dimartino V, et al. 2013. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Intl J Cancer 133:1259-1265.
53. Vosjan MJ, Perk LR, Roovers RC, Visser GW, Stigter-van Walsum M, van Bergen en Henegouwen PM, van Dongen GA. 2011. Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET. Eur J Nucl Med Molec Imaging 38:753-763.
54. Wagner JP, Wolf-Yadlin A, Sevecka M, Grenier JK, Root DE, Lauffenburger DA, MacBeath G. 2013. Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks. Science Signal 6:ra58 (1-17).
55. Walker F, Rothacker J, Henderson C, Nice EC, Catimel B, Zhang HH, Scott AM, et al. 2012. Ligand binding induces a conformational change in epidermal growth factor receptor dimers. Growth Factors 30:394-409.
56. Wang Y, Poulin E, Coffey R. 2013. LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor. Brit J Cancer 108:1765-1770.
57. Whatcott C, Han H, Posner RG, Von Hoff DD. 2013. Tumor-stromal interactions in pancreatic cancer. Crit Reviews™ Oncogenesis 18: 135-151.
58. Zigler M, Shir A, Levitzki A. 2013. Targeted cancer immunotherapy. Curr Opinion Pharmacol 13:504-510.
59. Zimmermann G, Papke B, Ismail S, Vartak N, Chandra A, Hoffmann M, Hahn SA, et al. 2013. Small molecule inhibition of the KRASPDE delta interaction impairs oncogenic KRAS signalling. Nature 497:638-642.
60. Ziomkiewicz I, Loman A, Klement R, Fritsch C, Klymchenko AS, Bunt G, Jovin TM, et al. 2013. Dynamic conformational transitions of the EGF receptor in living mammalian cells determined by FRET and fluorescence lifetime imaging microscopy. Cytometry A 83:794-805.